A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*

In this commentary, 2 experts discuss important recent clinical trials reported at ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

Dans ce commentaire, deux experts discutent d'importants essais cliniques récents qui furent rapportés lors de l'ASCO 2022, et qui pourraient avoir un impact sur le traitement de la leucémie lymphoïde chronique et du lymphome à cellules du manteau.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In dieser Stellungnahme erörtern 2 Experten wichtige neue klinische Studien, die auf der Jahrestagung der ASCO 2022 vorgestellt wurden und die möglicherweise die Behandlung der chronischen lymphatischen Leukämie und des Mantelzell-Lymphoms beeinflussen werden.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In questo approfondimento, 2 esperti discutono sui recenti e importanti risultati degli studi clinici presentati all'ASCO 2022, che potrebbero avere un impatto sul trattamento della leucemia linfocitica cronica e del linfoma a cellule mantellari.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

Neste comentário, dois especialistas discutem importantes ensaios clínicos recentes relatados na ASCO 2022 que podem impactar no tratamento da leucemia linfocítica crônica e do linfoma de células do manto.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

En este comentario, dos expertos hablan sobre los importantes ensayos clínicos recientes abordados en ASCO 2022 que podrían afectar al tratamiento de la leucemia linfocítica crónica y el linfoma de células del manto.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at EHA 2022 on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: July 20, 2022

Dans ce commentaire, deux experts discutent des implications des données d’essais cliniques présentées à l’EHA 2022 sur les traitements basés sur des inhibiteurs de BTK pour les patients atteints de leucémie lymphocytaire chronique (LLC) et de lymphome à cellules du manteau (LCM).

In dieser Stellungnahme diskutieren 2 Experten die Auswirkungen der auf der EHA 2022 vorgestellten Daten aus klinischen Studien zu BTK-Inhibitoren–basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

In questa intervista, due esperti discutono i dati degli studi clinici sugli inibitori di BTK nel trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) presentati al Congresso EHA 2022.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados no EHA 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la EHA 2022 sobre los tratamientos basados en inhibidores de la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at the 2022 Pan Pacific Lymphoma Conference on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 23, 2022

Dans ce commentaire, deux experts discutent des implications des données d'essais cliniques présentées lors de la Pan Pacific Lymphoma Conference de 2022 sur les traitements à base d'inhibiteurs de BTK pour les patients atteints de leucémie lymphocytaire chronique (LLC) ou de lymphome à cellules du manteau (LCM).

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 30, 2022

In dieser Stellungnahme diskutieren zwei Experten die Auswirkungen der auf der Pan Pacific Lymphoma Conference 2022 vorgestellten Daten aus klinischen Studien zu auf BTK-Inhibitoren basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

In questa intervista, due esperti discutono i dati degli studi clinici sugli inibitori di BTK nel trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) presentati alla Conferenza Pan Pacific Lymphoma 2022.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados na Conferência Pan-Pacífico sobre Linfomas 2022, sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la Conferencia del Pacífico sobre el Linfoma de 2022 a partir de los tratamientos basados en inhibidores de la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: October 19, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 1, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 2, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 2, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at the SOHO 2022 Annual Meeting on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 16, 2022

LLC et LCM : réunion annuelle de la SOHO 2022 Dans ce commentaire, deux experts discutent des implications des données d’essais cliniques présentées lors de la réunion annuelle de la SOHO 2022 sur les traitements à base d’inhibiteurs BTK pour les patients atteints de leucémie lymphoïde chronique (LLC) ou de lymphome à cellules du manteau (LCM).

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

In dieser Stellungnahme diskutieren 2 Experten die Auswirkungen der auf der Jahresversammlung der SOHO 2022 vorgestellten Daten aus klinischen Studien zu BTK-Inhibitor-basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

In questa discussione, due esperti discutono delle implicazioni derivanti dai dati degli studi clinici presentati alla Conferenza annuale della SOHO 2022 relativi ai trattamenti con inibitori di BTK nei pazienti con leucemia linfatica cronica e linfoma mantellare.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados na Reunião Anual da SOHO 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la Junta Anual de SOHO 2022 sobre los tratamientos basados en inhibidoresde la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022